Cambridge, Mass.-based Therion Biologics Corp. is expected to announce tomorrow that German billionaire Hans-Werner Hector will give the company $50 million to develop the first therapeutic cancer vaccine. The company's lead product in this area, Panvac-VF, has shown promising results in extending the lives of pancreatic cancer patients in early tests.

Related Summaries